EP1957487A1 - Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases - Google Patents
Nouvelle pyridopyrazine et son utilisation pour la modulation de kinasesInfo
- Publication number
- EP1957487A1 EP1957487A1 EP06819385A EP06819385A EP1957487A1 EP 1957487 A1 EP1957487 A1 EP 1957487A1 EP 06819385 A EP06819385 A EP 06819385A EP 06819385 A EP06819385 A EP 06819385A EP 1957487 A1 EP1957487 A1 EP 1957487A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- heterocyclyl
- group
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical class N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 title claims abstract 25
- 108091000080 Phosphotransferase Proteins 0.000 title claims 2
- 102000020233 phosphotransferase Human genes 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims abstract 8
- 238000011282 treatment Methods 0.000 claims abstract 6
- 238000002360 preparation method Methods 0.000 claims abstract 3
- 230000003211 malignant effect Effects 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 874
- 125000000623 heterocyclic group Chemical group 0.000 claims 603
- 125000001424 substituent group Chemical group 0.000 claims 485
- 125000003118 aryl group Chemical group 0.000 claims 469
- 125000001072 heteroaryl group Chemical group 0.000 claims 468
- 125000000753 cycloalkyl group Chemical group 0.000 claims 446
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 362
- 125000003710 aryl alkyl group Chemical group 0.000 claims 351
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 350
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 325
- 150000002431 hydrogen Chemical class 0.000 claims 324
- -1 arylalkyl heteroaryl Chemical group 0.000 claims 256
- 229910052740 iodine Inorganic materials 0.000 claims 177
- 229910052794 bromium Inorganic materials 0.000 claims 174
- 229910052801 chlorine Inorganic materials 0.000 claims 173
- 239000000460 chlorine Substances 0.000 claims 173
- 229910052731 fluorine Inorganic materials 0.000 claims 170
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 151
- 229910052739 hydrogen Inorganic materials 0.000 claims 112
- 239000001257 hydrogen Substances 0.000 claims 104
- 150000003254 radicals Chemical class 0.000 claims 100
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 71
- 125000002877 alkyl aryl group Chemical group 0.000 claims 66
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 48
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 48
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 37
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 claims 31
- 229910006069 SO3H Inorganic materials 0.000 claims 31
- 239000004202 carbamide Substances 0.000 claims 30
- 230000019491 signal transduction Effects 0.000 claims 23
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000003107 substituted aryl group Chemical group 0.000 claims 20
- 102000004190 Enzymes Human genes 0.000 claims 18
- 108090000790 Enzymes Proteins 0.000 claims 18
- 229940088598 enzyme Drugs 0.000 claims 18
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 15
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 11
- 150000005840 aryl radicals Chemical class 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 6
- 108010024976 Asparaginase Proteins 0.000 claims 6
- 108091007960 PI3Ks Proteins 0.000 claims 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 5
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims 5
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 5
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 5
- 230000001086 cytosolic effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 102000015790 Asparaginase Human genes 0.000 claims 4
- ZOUTYVWHWSUKPL-NOZJJQNGSA-N C[C@H](CS)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical group C[C@H](CS)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O ZOUTYVWHWSUKPL-NOZJJQNGSA-N 0.000 claims 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 4
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 101000721645 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Proteins 0.000 claims 4
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 claims 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
- 229910003849 O-Si Inorganic materials 0.000 claims 4
- 229910003872 O—Si Inorganic materials 0.000 claims 4
- UHBGYFCCKRAEHA-UHFFFAOYSA-N P-toluamide Chemical compound CC1=CC=C(C(N)=O)C=C1 UHBGYFCCKRAEHA-UHFFFAOYSA-N 0.000 claims 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 4
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 4
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 claims 4
- 101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 claims 4
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims 4
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims 4
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims 4
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims 4
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 claims 4
- 102100025059 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Human genes 0.000 claims 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 4
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 108010092160 Dactinomycin Proteins 0.000 claims 3
- APRJFNLVTJWEPP-UHFFFAOYSA-N Diethylcarbamic acid Chemical compound CCN(CC)C(O)=O APRJFNLVTJWEPP-UHFFFAOYSA-N 0.000 claims 3
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 3
- 101150113474 MAPK10 gene Proteins 0.000 claims 3
- 101150018665 MAPK3 gene Proteins 0.000 claims 3
- 101150031398 MAPK9 gene Proteins 0.000 claims 3
- 101150024075 Mapk1 gene Proteins 0.000 claims 3
- 101150101215 Mapk8 gene Proteins 0.000 claims 3
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims 3
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 claims 3
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 claims 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 3
- 229960000640 dactinomycin Drugs 0.000 claims 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 3
- 230000004963 pathophysiological condition Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- MFEJTEVLXIHCGR-UHFFFAOYSA-N (2,2-dimethyl-1,3-dioxolan-4-yl)methyl hydrogen carbonate Chemical compound CC1(C)OCC(COC(O)=O)O1 MFEJTEVLXIHCGR-UHFFFAOYSA-N 0.000 claims 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 2
- BKCCKXCKXUBOLF-UHFFFAOYSA-N 1-[3-[2-(diethylamino)ethoxy]propyl]-3-[3-(4-hydroxy-3-methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCCOCCN(CC)CC)=CC=C2N=CC=1C1=CC=C(O)C(OC)=C1 BKCCKXCKXUBOLF-UHFFFAOYSA-N 0.000 claims 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 2
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 claims 2
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 claims 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- SCEVBRBKKQZTKM-UHFFFAOYSA-N 5-[[6-chloro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-yl]oxy]-N-hydroxy-2-methylbenzamide Chemical compound ClC=1C(=CC2=C(NC(=N2)OC=2C=CC(=C(C(=O)NO)C=2)C)C=1)C=1C=C2C=CN(C2=CC=1)C SCEVBRBKKQZTKM-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- 206010001513 AIDS related complex Diseases 0.000 claims 2
- 108010005721 B 581 Proteins 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 claims 2
- 101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 claims 2
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 2
- 102100021906 Cyclin-O Human genes 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 239000012625 DNA intercalator Substances 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 241001331845 Equus asinus x caballus Species 0.000 claims 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims 2
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methyl urea Chemical compound CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 claims 2
- RHKWMLGKQSLTAN-UHFFFAOYSA-N OC(=O)OCCOCC1=CC=CC=C1 Chemical compound OC(=O)OCCOCC1=CC=CC=C1 RHKWMLGKQSLTAN-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 101710143448 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 claims 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960000473 altretamine Drugs 0.000 claims 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 2
- 229960003437 aminoglutethimide Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229960003272 asparaginase Drugs 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 2
- 229940120638 avastin Drugs 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims 2
- 229960000452 diethylstilbestrol Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 229930013356 epothilone Natural products 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- 229940082789 erbitux Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 229960002568 ethinylestradiol Drugs 0.000 claims 2
- KWBIXTIBYFUAGV-UHFFFAOYSA-N ethylcarbamic acid Chemical compound CCNC(O)=O KWBIXTIBYFUAGV-UHFFFAOYSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- 229960000961 floxuridine Drugs 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims 2
- 229960001751 fluoxymesterone Drugs 0.000 claims 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 2
- 229960002074 flutamide Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 229940022353 herceptin Drugs 0.000 claims 2
- 150000002390 heteroarenes Chemical class 0.000 claims 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 2
- 229960000908 idarubicin Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 229960002247 lomustine Drugs 0.000 claims 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 2
- 229960004961 mechlorethamine Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 2
- 229960004296 megestrol acetate Drugs 0.000 claims 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 229960004635 mesna Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229960000350 mitotane Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960002340 pentostatin Drugs 0.000 claims 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 2
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229960003171 plicamycin Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229960001052 streptozocin Drugs 0.000 claims 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 2
- 229960001278 teniposide Drugs 0.000 claims 2
- 229960001712 testosterone propionate Drugs 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 229960003087 tioguanine Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 2
- 229960004355 vindesine Drugs 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- AUHIPNBSUUUOOK-UHFFFAOYSA-N (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-[[3-(4-hydroxy-3-methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]carbamoylamino]butyl carbonate Chemical compound C1=C(O)C(OC)=CC(C=2N=C3N=C(NC(=O)NCCCCOC(=O)OCC4OC(C)(C)OC4)C=CC3=NC=2)=C1 AUHIPNBSUUUOOK-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 claims 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 claims 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 claims 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 claims 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 claims 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 claims 1
- YBBLOADPFWKNGS-UHFFFAOYSA-N 1,1-dimethylurea Chemical compound CN(C)C(N)=O YBBLOADPFWKNGS-UHFFFAOYSA-N 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- IGHUZFHESRDORI-UHFFFAOYSA-N 1-(3-benzylpyrido[2,3-b]pyrazin-6-yl)-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1CC1=CC=CC=C1 IGHUZFHESRDORI-UHFFFAOYSA-N 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- IQOMQYXFPQLGGX-UHFFFAOYSA-N 1-[3-(2-cyclopropylethynyl)pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1C#CC1CC1 IQOMQYXFPQLGGX-UHFFFAOYSA-N 0.000 claims 1
- BUSZBGJKPVUTBK-UHFFFAOYSA-N 1-[3-(4-cyclohexylanilino)pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1C1CCCCC1 BUSZBGJKPVUTBK-UHFFFAOYSA-N 0.000 claims 1
- VIMACOBYXBMQCJ-CMDGGOBGSA-N 1-[3-[(e)-2-cyclohexylethenyl]pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1\C=C\C1CCCCC1 VIMACOBYXBMQCJ-CMDGGOBGSA-N 0.000 claims 1
- ZBOFKBGQZADNFB-UHFFFAOYSA-N 1-[3-[3-(2-cyclohexylethoxy)anilino]pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=1)=CC=CC=1OCCC1CCCCC1 ZBOFKBGQZADNFB-UHFFFAOYSA-N 0.000 claims 1
- XEUGRVHOKBOVLR-UHFFFAOYSA-N 1-[3-[3-(diethylaminomethyl)-4-hydroxyanilino]pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC1=CC=C(O)C(CN(CC)CC)=C1 XEUGRVHOKBOVLR-UHFFFAOYSA-N 0.000 claims 1
- DEXNQCBWKKLLLW-UHFFFAOYSA-N 1-[3-[3-(dimethylamino)prop-1-ynyl]pyrido[2,3-b]pyrazin-6-yl]-3-ethylurea Chemical compound N1=CC(C#CCN(C)C)=NC2=NC(NC(=O)NCC)=CC=C21 DEXNQCBWKKLLLW-UHFFFAOYSA-N 0.000 claims 1
- CGKYZVIDTMLADP-UHFFFAOYSA-N 1-[4-[tert-butyl(dimethyl)silyl]oxybutyl]-3-(3-phenylpyrido[2,3-b]pyrazin-6-yl)urea Chemical compound N=1C2=NC(NC(=O)NCCCCO[Si](C)(C)C(C)(C)C)=CC=C2N=CC=1C1=CC=CC=C1 CGKYZVIDTMLADP-UHFFFAOYSA-N 0.000 claims 1
- WOUMMRMHTZIFDN-UHFFFAOYSA-N 1-[4-[tert-butyl(dimethyl)silyl]oxybutyl]-3-[3-(4-hydroxy-3-methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound C1=C(O)C(OC)=CC(C=2N=C3N=C(NC(=O)NCCCCO[Si](C)(C)C(C)(C)C)C=CC3=NC=2)=C1 WOUMMRMHTZIFDN-UHFFFAOYSA-N 0.000 claims 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- CQLATHFRGRKMCY-UHFFFAOYSA-N 1-ethyl-3-[3-(2-phenylethynyl)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1C#CC1=CC=CC=C1 CQLATHFRGRKMCY-UHFFFAOYSA-N 0.000 claims 1
- NSHMETNGGPRFQD-UHFFFAOYSA-N 1-ethyl-3-[3-(2-thiophen-3-ylethynyl)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1C#CC=1C=CSC=1 NSHMETNGGPRFQD-UHFFFAOYSA-N 0.000 claims 1
- JVUKHQQRFWUUDQ-UHFFFAOYSA-N 1-ethyl-3-[3-(3-morpholin-4-ylanilino)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=1)=CC=CC=1N1CCOCC1 JVUKHQQRFWUUDQ-UHFFFAOYSA-N 0.000 claims 1
- ZMFGRMNHJUUFEL-UHFFFAOYSA-N 1-ethyl-3-[3-(4-imidazol-1-ylanilino)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1N1C=CN=C1 ZMFGRMNHJUUFEL-UHFFFAOYSA-N 0.000 claims 1
- GZBAPPUCNYMTFY-UHFFFAOYSA-N 1-ethyl-3-[3-(4-morpholin-4-ylsulfonylanilino)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 GZBAPPUCNYMTFY-UHFFFAOYSA-N 0.000 claims 1
- AHCAETAPHBILIV-UHFFFAOYSA-N 1-ethyl-3-[3-(4-pyrrolidin-1-ylanilino)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1N1CCCC1 AHCAETAPHBILIV-UHFFFAOYSA-N 0.000 claims 1
- DLVWEVPIBDBCBI-UHFFFAOYSA-N 1-ethyl-3-[3-(4-thiophen-3-ylanilino)pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1C=1C=CSC=1 DLVWEVPIBDBCBI-UHFFFAOYSA-N 0.000 claims 1
- JEUJPDRXCDEJER-UHFFFAOYSA-N 1-ethyl-3-[3-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=N1)=CC=C1N1CCOCC1 JEUJPDRXCDEJER-UHFFFAOYSA-N 0.000 claims 1
- ZATLMIGIWOLVAL-VMPITWQZSA-N 1-ethyl-3-[3-[(e)-2-(4-fluorophenyl)ethenyl]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1\C=C\C1=CC=C(F)C=C1 ZATLMIGIWOLVAL-VMPITWQZSA-N 0.000 claims 1
- GMQMXBSEXRVXKC-SNAWJCMRSA-N 1-ethyl-3-[3-[(e)-3-methoxyprop-1-enyl]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N1=CC(\C=C\COC)=NC2=NC(NC(=O)NCC)=CC=C21 GMQMXBSEXRVXKC-SNAWJCMRSA-N 0.000 claims 1
- KXSBCNXVJMBCJX-UHFFFAOYSA-N 1-ethyl-3-[3-[2-(4-fluorophenyl)ethyl]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1CCC1=CC=C(F)C=C1 KXSBCNXVJMBCJX-UHFFFAOYSA-N 0.000 claims 1
- AUUXDBHQWXPJHW-UHFFFAOYSA-N 1-ethyl-3-[3-[3-(1,2,4-triazol-1-ylmethyl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=1)=CC=CC=1CN1C=NC=N1 AUUXDBHQWXPJHW-UHFFFAOYSA-N 0.000 claims 1
- LLNFFOKBWSXAGX-UHFFFAOYSA-N 1-ethyl-3-[3-[3-(2h-tetrazol-5-yl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=1)=CC=CC=1C1=NN=NN1 LLNFFOKBWSXAGX-UHFFFAOYSA-N 0.000 claims 1
- MNDAIZSXEFZEMD-UHFFFAOYSA-N 1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=1)=CC=CC=1CN1CCCCC1 MNDAIZSXEFZEMD-UHFFFAOYSA-N 0.000 claims 1
- RCYSRRGYVVRPJL-UHFFFAOYSA-N 1-ethyl-3-[3-[4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1N1CCN(C)CC1 RCYSRRGYVVRPJL-UHFFFAOYSA-N 0.000 claims 1
- PKOFFKLWACPLQZ-UHFFFAOYSA-N 1-ethyl-3-[3-[4-(morpholin-4-ylmethyl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1CN1CCOCC1 PKOFFKLWACPLQZ-UHFFFAOYSA-N 0.000 claims 1
- RQBCXUCSBMSRIN-UHFFFAOYSA-N 1-ethyl-3-[3-[4-(morpholin-4-ylmethyl)phenyl]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1C(C=C1)=CC=C1CN1CCOCC1 RQBCXUCSBMSRIN-UHFFFAOYSA-N 0.000 claims 1
- GHALWVVVGDYINF-UHFFFAOYSA-N 1-ethyl-3-[3-[4-(piperidin-1-ylmethyl)anilino]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1NC(C=C1)=CC=C1CN1CCCCC1 GHALWVVVGDYINF-UHFFFAOYSA-N 0.000 claims 1
- IMUCFSHQPYPPOU-UHFFFAOYSA-N 1-ethyl-3-[3-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]pyrido[2,3-b]pyrazin-6-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2N=CC=1C1=CC=C(OCCOCCOC)C=C1 IMUCFSHQPYPPOU-UHFFFAOYSA-N 0.000 claims 1
- XUFXDODGXLVPNJ-UHFFFAOYSA-N 1-ethyl-3-phenylurea Chemical compound CCNC(=O)NC1=CC=CC=C1 XUFXDODGXLVPNJ-UHFFFAOYSA-N 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- XRMDCWJNPDVAFI-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxopiperidin-1-ium-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)[N+]1=O XRMDCWJNPDVAFI-UHFFFAOYSA-N 0.000 claims 1
- FFGSTADVJLHEQC-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-[[3-(4-hydroxy-3-methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]carbamoylamino]butyl carbonate Chemical compound C1=C(O)C(OC)=CC(C=2N=C3N=C(NC(=O)NCCCCOC(=O)OCC(O)CO)C=CC3=NC=2)=C1 FFGSTADVJLHEQC-UHFFFAOYSA-N 0.000 claims 1
- AOBOXSNTOBSLGL-UHFFFAOYSA-N 2,3-dihydroxypropyl hydrogen carbonate Chemical compound OCC(O)COC(O)=O AOBOXSNTOBSLGL-UHFFFAOYSA-N 0.000 claims 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 claims 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 claims 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 claims 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 1
- QAQJKDRAJZWQCM-UHFFFAOYSA-N 2-methoxyethyl carbamate Chemical compound COCCOC(N)=O QAQJKDRAJZWQCM-UHFFFAOYSA-N 0.000 claims 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- UHPNJZOWQAAGNQ-UHFFFAOYSA-N 3-[2-(diethylamino)ethoxy]propylideneurea Chemical compound C(C)N(CCOCCC=NC(=O)N)CC UHPNJZOWQAAGNQ-UHFFFAOYSA-N 0.000 claims 1
- MINMDCMSHDBHKG-UHFFFAOYSA-N 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(=C(S1)C)N=C1N1CCOCC1 MINMDCMSHDBHKG-UHFFFAOYSA-N 0.000 claims 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 claims 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 claims 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 101100478290 Arabidopsis thaliana SR30 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 claims 1
- CQBMHHFZOOMCHD-UHFFFAOYSA-N C1=CC=C(C=C1)C2=CN=C3C=CC(=NC3=N2)NC(=O)C(=O)N Chemical compound C1=CC=C(C=C1)C2=CN=C3C=CC(=NC3=N2)NC(=O)C(=O)N CQBMHHFZOOMCHD-UHFFFAOYSA-N 0.000 claims 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 claims 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims 1
- 101100240521 Caenorhabditis elegans nhr-16 gene Proteins 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- OEBVYNULNKSONR-UHFFFAOYSA-N ClC1=C(CN2C(C(C3=CC=C(C=C23)C(=O)NCC2=C(C=C(C=C2F)F)F)(C)C)=O)C(=CC=C1)F Chemical compound ClC1=C(CN2C(C(C3=CC=C(C=C23)C(=O)NCC2=C(C=C(C=C2F)F)F)(C)C)=O)C(=CC=C1)F OEBVYNULNKSONR-UHFFFAOYSA-N 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 229940126639 Compound 33 Drugs 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 241000283074 Equus asinus Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- XEDJGCIOZDHXOR-JTQLQIEISA-N N-(2-chloro-4-methylpyridin-3-yl)-6-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridine-3-carboxamide Chemical compound ClC1=NC=CC(=C1NC(C1=C(N=C(C(=C1)F)N1N=C(N(C1=O)CC)CO)O[C@H](C(F)(F)F)C)=O)C XEDJGCIOZDHXOR-JTQLQIEISA-N 0.000 claims 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 claims 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 101100188958 Onchocerca volvulus OV71 gene Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 108010045306 T134 peptide Proteins 0.000 claims 1
- 108010025037 T140 peptide Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 claims 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 claims 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 101150045355 akt1 gene Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- YDIXDMFYBXZMHT-UHFFFAOYSA-N but-2-ynyl hydrogen carbonate Chemical compound CC#CCOC(O)=O YDIXDMFYBXZMHT-UHFFFAOYSA-N 0.000 claims 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 230000004715 cellular signal transduction Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 229940125961 compound 24 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940125851 compound 27 Drugs 0.000 claims 1
- 229940127204 compound 29 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 229940125807 compound 37 Drugs 0.000 claims 1
- 229940127573 compound 38 Drugs 0.000 claims 1
- 229940126540 compound 41 Drugs 0.000 claims 1
- 229940125936 compound 42 Drugs 0.000 claims 1
- 229940125844 compound 46 Drugs 0.000 claims 1
- 229940127271 compound 49 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 229940126545 compound 53 Drugs 0.000 claims 1
- 229940127113 compound 57 Drugs 0.000 claims 1
- 229940125900 compound 59 Drugs 0.000 claims 1
- 229940126179 compound 72 Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 claims 1
- DWLVWMUCHSLGSU-UHFFFAOYSA-N dimethylcarbamic acid Chemical compound CN(C)C(O)=O DWLVWMUCHSLGSU-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005469 ethylenyl group Chemical group 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229940080856 gleevec Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 125000006038 hexenyl group Chemical group 0.000 claims 1
- 125000005980 hexynyl group Chemical group 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229940084651 iressa Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- LDBMMUWSKFDLCV-UHFFFAOYSA-N n-ethyl-n'-(3-phenylpyrido[2,3-b]pyrazin-6-yl)oxamide Chemical compound N=1C2=NC(NC(=O)C(=O)NCC)=CC=C2N=CC=1C1=CC=CC=C1 LDBMMUWSKFDLCV-UHFFFAOYSA-N 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Substances OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims 1
- 125000005981 pentynyl group Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960003440 semustine Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 230000025185 skeletal muscle atrophy Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940120982 tarceva Drugs 0.000 claims 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- Novel pyridopyrazines and their use as modulators of kinases are novel pyridopyrazines and their use as modulators of kinases.
- the invention relates to kinase modulators of the pyrido [2,3-b] pyrazine type, to their preparation and use as medicaments for modulating misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine, serine / threonine and lipid kinases and to Treatment of malignant or benign tumors and other diseases based on pathological cell proliferation diseases such.
- the phosphorylation of proteins is generally initiated by extracellular signals and provides a universal mechanism for the control of various cellular events, such as cell proliferation. As metabolic processes, cell growth, cell migration, cell differentiation, membrane transport and apoptosis. For protein phosphorylation, the protein family of kinases is responsible. These enzymes catalyze the phosphate transfer to specific substrate proteins. Based on substrate specificity, the kinases are divided into three major classes, the tyrosine kinases, the serine / threonine kinases, and the lipid kinases.
- Both the receptor tyrosine kinases and the cytoplasmic tyrosine, serine / threonine and lipid kinases are important proteins of the signal transduction of the cell. Overexpression or degeneration of these proteins plays an important role in disorders based on pathological cell proliferation. These include metabolic diseases, connective tissue and blood vessel diseases, as well as malignant and benign tumors. They occur in tumor development and development often as oncogenes, ie as aberrant, constitutively active kinase proteins. The consequences of this excessive Kinaseeducation ist are z. For example, uncontrolled cell growth and reduced cell death. The stimulation of tumor-induced growth factors can also be the cause of the overstimulation of kinases. The development of kinase modulators is therefore of particular interest for all pathogenic processes that are influenced by kinases.
- diseases such as cancer, neurodegeneration and inflammatory diseases
- the individual components of these signaling cascades represent important therapeutic targets for the intervention of the various disease processes (Weinstein-Oppenheimer CR et al 2000, Chang F. et al., 2003, Katso R. et al., 2001 and Lu Y. et al., 2003).
- a variety of growth factors, cytokines and oncogenes transduce their growth-promoting signals via activation of G-protein coupled ras, which is used to activate the serine-threonine kinase Raf and to activate mitogen-activated protein kinase kinase 1 and 2 (MAPKK1 / 2 or Mek1 / 2) and in the phosphorylation and activation of MAPK 1 and 2 - also known as Extracellular Signal Regulated Kinase (Erk1 and 2).
- G-protein coupled ras which is used to activate the serine-threonine kinase Raf and to activate mitogen-activated protein kinase kinase 1 and 2 (MAPKK1 / 2 or Mek1 / 2) and in the phosphorylation and activation of MAPK 1 and 2 - also known as Extracellular Signal Regulated Kinase (Erk1 and 2).
- the ras-Raf-Mek-Erk pathway combines a large number of proto-oncogenes, including ligands, tyrosine kinase receptors, G proteins, kinases, and nuclear transcription factors.
- Tyrosine kinases such as EGFR (Menelsohn J. et al., 2000) often mediate constitutive active signals to the downstream ras-Raf-Mek- Erk signaling pathway in tumors due to overexpression and mutation. Ras mutations are mutated in 30% of all human tumors (Khleif SN et al., 1999, Marshall C, 1999), the highest incidence being 90% in pancreatic carcinomas (Friess H.
- Raf kinases also have Mek-Erk independent, anti-apoptotic functions, whose molecular steps are not yet fully described.
- Ask1, Bcl-2, Akt and Bag1 have been described as possible interaction partners for the Mek-Erk-independent Raf activity (Chen J et al., 2001, Troppajier J. et al., 2003, Rapp UR et al., 2004, Gotz R. et al., 2005). It is now believed that both Mek-Erk-dependent and Mek-Erk-independent signal transduction mechanisms control the activation of the ras and Raf stimuli located above.
- the isoenzymes of phosphatidylinositol 3-kinases function predominantly as lipid kinases and catalyze the D3 phosphorylation of second messenger lipids Ptdlns (phosphatidylinositol) to Ptdlns (3) P, Ptdlns (3,4) P 2 , Ptdlns (3,4 , 5) P 3 phosphatidylinositol phosphates.
- the class I PI3Ks are structurally composed of the catalytic (pHOalpha, beta, gamma, delta) and regulatory (p85alpha, beta or p101gamma) subunits.
- class II (PI3K-C2alpha, PI3K-C2beta) and class IN (Vps34p) enzymes belong to the family of PI3 kinases (Wymann MP et al., 1998, Van Haesebroeck B. et al., 2001).
- the PIP increase triggered by PI3Ks activates the proliferative ras-Raf-Mek-Erk signaling pathway via the coupling of ras (Rodriguez-Viciana P.
- PI3Ks fulfills at least 2 crucial mechanisms of tumorigenesis, namely the activation of cell growth and cell differentiation and the inhibition of apoptosis.
- the PI3K also have protein-phosphorylating properties (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, Van Haesebroeck B.
- PI3Ks also have kinase-independent, regulatory effector properties, for example in the control of cardiac contraction (Crackower - A -
- PI3Kdelta and PI3Kgamma are specifically expressed on hematopoietic cells and thus potential targets for isoenzyme-specific PI3Kdelta and PI3Kgamma inhibitors in the treatment of inflammatory diseases such as rheumatism, asthma and allergies and in the treatment of B- and T- Cell lymphomas (Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005).
- PI3Kalpha which has recently been identified as a proto-oncogene (Shayesteh L.
- PI3K-related kinases include the serine / threonine kinases mTOR, ATM, ATR, h-SMG-1, and DNA-PK (Chiang G.G. et al., 2004).
- PIKK PI3K-related kinases
- Their catalytic domains have high sequence homology to the catalytic domain of the PI3Ks.
- Phosphorylation contributes to the overactivation of Akt and its downstream cascade components, thus underlining the causal role of PI3K as a target for tumor therapy.
- the kinase inhibitor Bay 43-9006 (WO 99/32111, WO 03/068223) already in clinical trials shows a relatively nonspecific inhibition pattern of serine / threonine and tyrosine kinases such as Raf, VEGFR2 / 3, Flt-3 , PDGFR, c-Kit and other kinases.
- This inhibitor is of great importance in angiogenesis-induced advanced tumor diseases (eg in renal cell carcinoma) but also in melanomas with a high B-Raf mutation rate.
- the clinical effect of Bay 43-9006 is currently also being investigated in patients with refractory solid tumors in combination with eg docetaxel. So far, mild side effects and promising anti-tumoral effects have been described. Inhibition of the kinases in the PI3K-Akt signaling pathway is not described or disclosed for Bay 43-9006.
- the Mek1 / 2 inhibitor PD0325901 (WO 02/06213) is currently undergoing Phase I clinical trials.
- the precursor CM 040 (WO 00/35435, WO 00/37141) was noted for its high Mek specificity and target affinity , However, this compound proved to be metabolically unstable in Phase I / II studies.
- Clinical data of the current successor substance PD0325901 are pending. However, neither an interaction with Erk1 or Erk2, nor a PI3K-Akt signaling pathway inhibiting function or its simultaneous modulation is published or disclosed for this Mek inhibitor.
- ICOS disclosed a PI3K inhibitor IC87114 with high PI3Kdelta isoenzyme specificity (WO 01/81346).
- PI103 Yamanouchi / Piramed describe a selectivity versus the PI3Kalpha isoform.
- a highly regarded research environment exists (see review R. Wetzker et al., 2004).
- Inhibitors of the SAPK signaling pathway are described in the literature (Gum RJ., 1998, Bennett BL et al 2001, Davies SP et al 2000). However, for these SAPK inhibitors, no PI3Ks-inhibiting function and also no specific inhibition of Erk1 or Erk2 or simultaneous inhibition of SAPKs, Erk1, Erk2, or PI3Ks is disclosed. In the 6- or 7-position substituted pyrido [2,3-b] pyrazine derivatives are widely used as pharmacologically active compounds and as building blocks in pharmaceutical chemistry.
- patents WO 04/104002 and WO 04/104003 describe pyrido [2,3-b] pyrazines, which may be substituted in the 6- or 7-position by urea, thiourea, amidine or guanidine groups. These compounds possess properties as inhibitors or modulators of kinases, in particular of tyrosine and serine / threonine kinases, and a use as medicaments is indicated. In contrast, a use of these compounds as modulators of lipid kinases, alone or in combination with tyrosine and serine / threonine kinases, is not described.
- patent WO 99/17759 describes pyrido [2,3-b] pyrazines which carry, inter alia, alkyl, aryl and heteroaryl-substituted carbamates in the 6-position. These compounds will be used to modulate the function of serine-threonine protein kinases.
- 6- and 7-position urea-substituted pyrido [2,3-b] pyrazines are given in the patent WO 05/056547 (Bemis et al.).
- the compounds in this patent have additional carbonyl, sulfoxy, sulfonic or imine substitution in the 2- or 3-position, whereby the compounds are structurally distinct from the pyrido [2,3-b] pyrazines of the invention described in this invention differ.
- the pyridopyrazines indicated in WO 05/056547 are described as inhibitors of protein kinases, in particular of GSK-3, Syk and JAK-3.
- the invention is therefore directed to providing novel compounds which are useful as modulators of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases. Since not all in dysregulated signal transduction cascades connected in series kinases - such. For example, in Raf-Mek-Erk or PI3K-Akt - must be present as oncogenic kinases or as constitutively active enzymes, in this invention, the non-active kinases are considered as therapeutic target proteins, i. The new compounds can bind to both active and non-active kinases, thereby influencing signal transduction.
- the invention is further directed to providing novel compounds which possess as a modulator of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases the property of both a single and two or more kinases, in particular Erk1 / 2 and PI3K, from one or several signal transduction cascades, in particular ras Raf Mek Erk and PI3K act to influence.
- a dual mechanism, i. H. the simultaneous inhibition of two or more signal-induction cascades in comparison to the therapeutic attack of only one signal transduction pathway should lead to an increase in the effect in the treatment of all pathogenic processes which are influenced by kinases.
- a first aspect of the present application describes novel compounds from the series of pyrido [2,3-b] pyrazines according to the general formula (I),
- radicals Z3, Z4 or both radicals Z3, Z4 is independently “substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
- Substituted aryl is substituted with “heterocyclylalkyl", the other radical Z3 or Z4 is not “substituted or unsubstituted aryl", where optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further substituted independently of one another with min. at least one substituent, identical or different, selected from the group consisting of:
- X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, x149, X150, X151, X152, x153 are X154 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, X109, X110 and / or X1 18, X119 and / or X131, X132 and / or X138, X139 and / or X147,
- alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX155, -NX156X157, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
- OS OS (O 2) -X177, -NHC (O) -XI78, -NX179C (O) -XI80, -NH-C (O) -O- X181, -NH-C (O) -NH-XI82, -NH -C (O) -NXI83X184, -NX185-C (O) - O-X186, -NX187-C (O) -NH-XI88, -NX189-C (O) -NXI90X191, - NHS (O 2) -X192 , -NX193S (O 2) -X194, -S-x195, -S (O) -XI96, -S (O 2) - X197, -S (O 2) NH-XI 98, -S (O 2) NXI 99X200, -S (O 2) O-X201, - P (O) (OX202) (OX203),
- X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206 are independently selected from the group consisting of: alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X161,
- X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 may together also form "heterocyclyl";
- radicals Z3, Z4 or both radicals Z3, Z4 are independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
- X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, x243, X244, X245, X246, are x247, x248 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X216, X217 and / or X221, X222 and / or X227, X228
- X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 independent are independently selected from the group consisting of: "(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary
- Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of: (e) hydrogen;
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX509, -NX510X511, -NO 2 , -OH, -OCF 3 , -
- X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are independently selected the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 in each case also" heterocyclyl " can form;
- substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, are X663, X664 are independently selected from the group consisting of: "alkyl, (30 Cg-C) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X619, X620 and / or X628, X629 and / or
- X641, X642 and / or X648, X649 and / or X657, X658 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with at least one at least one substituent, the same or different, selected from the group consisting of:
- X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are independently selected consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X671, X672 and / or X680, X681 and / or X693, X694 and / or X700, X701 and / or X709, X710 may together also form "heterocyclyl
- X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl
- X762 together can also form "heterocyclyl"
- heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
- X808, X809, X810, X81 1, X812, X813, X814, X815, X816, X817, X818, X819, X820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X775, X776 and / or X784, X785 and / or
- X797, X798 and / or X804, X805 and / or X813, X814 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X91 1, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 are independently selected from the group consisting of: "alkyl , (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, aryl
- X918 may together also form "heterocyclyl"
- Z6 is independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- X1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, X1027, X1028 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively, X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 may each together also form" heterocyclyl ";
- Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C” 9 " -C” 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, x1080 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl,
- X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) 25 optionally substituted independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132 are independently selected from the group consisting of : "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X1087, X1088 and / or X1096, X1097 and / or X1 109, X1 110 and / or X11 16, X11 17 and / or X1125, X1 126 may each together also form "heterocycly
- NZ8Z9 wherein Z8, Z9 are independently selected from the group consisting of:
- OSi (X1 158) (X1159) (X1160), -0S (0 2 ) -X1161, -NHC (O) -X1 162, -NX1 163C (O) -X1 164, -NH-C (O) -O- X1165, -N HC (O) -NH-X1 166, -NH-C (O) -NX1 167X1168, -NX1 169-C (O) -O-X1170, -NX1 171-C (O) -NH- X1172, -NX1 173-C (O) -NXI 174X1175, - NHS (0 2 ) -X 1 176, -NX 1 177S (O 2 ) -X 1178, -S-X 1 179, -S (O) -
- X1 154, X1 155, X1 156, X1 157, X1158, X1159, X1160, X1161, X1 162, X1 163, X1 164, X1 165, X1166, X1167, X1168, X1169, X1 170, X1 171, X1 172, X1 173, X1174, X1175, X1176, X1177, X1 178, X1 179, X1 180, X1 181, X1182, X1183, X1184, X1185, X1 186, X1 187, X1 188, X1 189, X1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal
- alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 1 CN CF 3, N 3, NH 2 , -NHX1 191, -NX1 192X1193, -NO 2 , -
- one of Z3, Z4 or both Z3, Z4 are independently "substituted heteroaryl", wherein “substituted heteroaryl” is substituted with at least one substituent selected from the group consisting of: (a) "alkyl, cycloalkyl, heterocyclyl , aryl, heteroaryl, -NH-V1, -N (alkyl) 2 , -
- Substituents the same or different, selected from the group consisting of: (i) "(C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, -NH-cycloalkylalkyl, -NH-heteroaryl, -NH- heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heteroarylalkyl, -
- Z3, Z4 independently of one another may also be further substituted by at least one substituent, identical or different, selected from the group consisting of: (b) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHV53, -NV54V55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, - CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -V56, -C (O) O-V57, -C (O) NH-V58, -C (O) NV59V60
- V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are independent are selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V59, V60 and / or
- V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 may together also form "heterocyclyl" wherein optional substituents above the substituent group (b) may be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
- V148, V149, V150, V151, V152, V153, V154, V155, V156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and wherein alternatively V1 11, V1 12 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 may together also form" heterocyclyl "; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
- radicals Z3, Z4 or both radicals Z3, Z4 independently of one another are "substituted heteroaryl", where "substituted heteroaryl” is substituted by at least one substituent, identical or different, selected from the group consisting of:
- V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are selected independently the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V218,
- V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 may together also form "heterocyclyl", with the proviso that the substituents "- N (alkyl) 2 "," - C (O) N (alkyl) 2 ",” - C (O) N (cycloalkyl) 2 ",” - C (O) N (aryl) 2 ", C (O) N (heteroaryl) 2 "are further substituted by at least one substituent selected from sub-substituent group (i); wherein optionally substituted substituents of the substituent group (c) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
- V279 -NH-C (O) -NH-V280, -NH-C (O) -NV281V282, -NV283-C (O) -O-V284, -NV285-C (O) -NH-V286, -NV287 -C (O) -NV288V289, - NHS (O 2) -V290, -NV291S (O 2) -V292, -S-V293, -S (O) -V294, -S (O 2) - V295, -S (O 2) N H-V296, -S (O 2) NV297V298, -S (O 2) O-V299, - P (O) (OV300) (OV301), -Si (V302) (V303 ) (V304) "; wherein V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V26
- V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are independently selected from the group consisting of: " alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V259,
- V260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 may together also form "heterocyclyl", optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 independently from each other can also be further substituted with at least one substituent, identical or different, selected from
- V350 may also together form "heterocyclyl", where optionally substituted substituents of the substituent group (d) may in turn be substituted by at least one substituent, identical or different, selected from the group consisting of:
- V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are independently selected from the group consisting of: "alkyl,
- V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively V415, V416 and / or V424, V425 and / or V437, V438 and / or V444, V445 and / or V453, V454 may together also form "heterocyclyl";
- Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
- (g) unsubstituted or substituted alkyl or (Cg-C3o) alkyl may be optionally substituted with (C 9 -C 30 C) alkyl moiety of the alkyl or at least one substituent, identical or different, selected from the group-consisting of pe:
- V463, V464 and /: are V506, V507, V508 independently selected from the group consisting of or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 may each together also form "heterocyclyl"; optionally substituents of the substituent group (i) above may be substituted independently of one another with at least at least one substituent, the same or different, selected from the group consisting of:
- V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560 are independently selected from consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V515, V516 and / or V524, V525, and / or V537, V538 and / or V544, V545 and / or V553, V554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent
- V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, V567, V568 and / or V576, V577 and / or V589, V5
- V606 may together also form "heterocyclyl"
- V662 V663 (V664) "; wherein V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631 , V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651,
- V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and wherein alternatively V619, V620 and / or V628, V629 and / or
- V641, V642 and / or V648, V649 and / or V657, V658 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V71 1, V712, V713, V714, V715, V716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
- V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709, V710 also together also "heterocyclyl "can form; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V723, V724 and / or V732, V733 and / or V745, V7
- V762 may together also form "heterocyclyl"
- heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
- V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively V775, V776 and / or V784, V785 and or V797, V798 and / or V804, V805 and / or V813, V814 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent,
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV821, -NV822V823, -NO 2 , -OH, -OCF 3 , -
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
- V827, V828 and / or V836, V837 and / or V849, V850 and / or V856, V857 and / or V865, V866 may together also form "heterocyclyl";
- substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
- NV905-C O-NH-V906, -NV907-C (O) -NV908V909, - NHS (O 2) -V910, -NV911S (O 2) -V912, -S-V913, -S (O) - V914, -S (O 2) -V915, -S (O 2) NH-V916, -S (O 2) NV917V918, -S (O 2) O- V919, -P (O) (OV920) (OV921) , -Si (V922) (V923) (V924) ";
- V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are independently selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively V879, V880 and / or V888, V889 and / or V901, V902 and
- alkyl (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
- V931, V932 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 may together also form "heterocyclyl";
- substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
- V1025 30 P (O) (OVI 024) (OV1025), -Si (VI 026) (V1027) (V1028) "; wherein V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkyl
- Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C” 9 " -C” 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV1029, -NV1030V1031, -NO 2 , -OH, -
- NV1044V1045 -OP (O) (OVI 046) (OV1047), - OSi (VI 048) (V1049) (V1050), -OS (O 2) -V1051, -N HC (O) -VI 052, - NV1053C ( O) -VI 054, -NH-C (O) -O-VI 055, -NH-C (O) -NH-V1056, -NH-C (O) -NVI 057V1058, -NV1059-C (O) - O-VI 060, - NV1061-C (O) -NH-VI 062, -NV1063-C (O) -NVI 064V1065, -
- V1060 V1061, V1062, V1063, V1064, V1065, V1066, V1067,
- alkyl (- C 30 9 C) alkyl, cycloalkyl, cycloalkylalkyl, "alkyl,: are V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080 independently selected from the group consisting of , heterocyclyl, heterocyclylalkyl, 10 aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
- V1035, V1036 and / or V1044, V1045 and / or V1057, V1058 and / or V1064, V1065 and / or V1073, V1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 15 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- V1131 35 Si (VI 130) (V1131) (V1132) "; wherein V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105 , V1106, V1107, V1108, V1109, V1110, V1111, VII ⁇ 1 VIIIa 1 VIIU 1 VIIIS 1 VIIIe 1 VIIIy 1 VIIIe 1 VIIIg 1
- V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131, V1132 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V1087, V1088 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 also together also" heterocyclyl "can form;
- V1180 -S (0 2) -V1 181, -S (O 2) NH-V1 182, -S (O 2) NVI 183V1184, - S (O 2) O-V1185, -P (O) (OV1186) (OV1 187), -Si (VI 188) (V1189) (V1190) ", wherein V1139, V1140, V1141, V1142, V1143, V1144, V1145,
- V1186, V1187, V1188, V1 189 V1 190 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, V1145, V1146 and / or V1 154, V1 155 and / or V1 167, V1 168
- V1 174, V1 175 and / or V1 183, V1184 may together also also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different - 30 selects from the group consisting of:
- V1238, V1239, V1240, V1241 are, V1242 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V1197, V1198 and / or V1206, V1207 and / or
- V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 may together also form "heterocyclyl";
- one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted alkyl", where "substituted alkyl” is substituted by at least one substituent selected from the group consisting of: (a) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW1, -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 4, -C (O) (
- W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively W7, W8 and or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 may together also form "heterocyclyl”; with the proviso that "--C (O) NH-aryl", "- C (O) NH-heteroaryl", "
- W99, W100, W101, W102, W103, W104 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal- kyl, heteroaryl, heteroarylalkyl and alternatively W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -
- W153, W154, W155, are W156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 11 , W1 12 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 may together also form "heterocyclyl";
- Z3, Z4 or both radicals Z3, Z4 are independently "(C 9 -C 3 o) alkyl" are one another, wherein "(Cg-C 3 o) alkyl” may optionally be independently substituted with at least one substituent , the same or different, selected from the group consisting of:
- alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 .
- W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and alternatively W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may together also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in
- alkyl consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 can in each case together also form "heterocyclyl";
- Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
- alkyl or (Cg-C 3 o) alkyl group may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW457, -NW458W459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (
- W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508 are independently selected from the group consisting of: "alkyl, (Cg-C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W463,
- W464 and / or W472, W473 and / or W485, W486 and / or W492, W493 and / or W501, W502 may in each case also form "heterocyclyl", where optionally the above substituents of the substituent group (i) in turn are substituted independently of one another may be substituted by at least one substituent, the same or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW509, -NW510W511, -NO 2 , -OH, -OCF 3 ,
- W553, W554, W555, W556, W557, W558, W559, W560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W515, W516 and / or W524, W525 and / or W537,
- W538 and / or W544, W545 and / or W553, W554 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected selects from the group consisting of:
- alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW561, -NW562W563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
- W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1, W612 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl , heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 may each together
- W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664 independent are selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W619, W620 and / or W628, W629 and / or W641, W642 and / or W648, W649 and / or W657, W658 may each also together form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substitu
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
- W709, W710, W71 1, W712, W713, W714, W715, W716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and where 10 alternatively W671, W672 and / or W680, W681 and / or W693,
- W694 and / or W700, W701 and / or W709, W710 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
- At least one substituent identical or different, selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW717, -NW718W719, -NO 2 , -
- OSi (W736) (W737) (W738), -OS (O2) -W739, -NHC (O) -W740, -NW741C (O) -W742, -NH-C (O) -O-W743, -NH -C (O) -NH-W744, -NHC (O) -N W745W746, -NW747-C (O) -O-W748, -NW749-C (O) -NH-W750, -NW751 -C (O ) -N W752W753, -
- W757, W758, W759, W760, W761, W762, W763, W764 are, W765, W766, W767, W768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
- W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 may together also form "heterocyclyl";
- heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
- OSi (W788) (W789) (W790), -OS (O2) -W791, -NHC (O) -W792, - NW793C (O) -W794, -NH-C (O) -O-W795, -N HC (O) -NH-W796, -NHC (O) -N W797W798, -NW799-C (O) -O-W800, -NW801-C (O) -NH-W802, -NW803-C (O ) -NW804W805, -NHS (O2) -W806, - NW807S (O2) -W808, -S-W809, -S (0) -W810, -S (O2) -W81 1 -
- W879, W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 may together also form "heterocyclyl";
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW925, -NW926W927, -NO 2 , -OH, -OCF 3 ,
- W970, W971, W972, W973, W974, W975, W976 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively 10 W931, W932 and / or W940, W941 and / or W953,
- W954 and / or W960, W961 and / or W969, W970 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
- At least one substituent identical or different, selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW977, -NW978W979, -NO 2 , -
- OSi (W996) (W997) (W998), -OS (O2) -W999, -NHC (O) -WIOOO, -NW1001 C (O) -WI 002, -NH-C (O) -O-WI 003 , -NH-C (O) -NH-W1004, -NH-C (O) -NWI 005W1006, -NW1007-C (O) -O-W1008, -NW1009-C (O) -NH-WI 010, - NW1011-C (O) -
- W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, are W1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022, respectively together may also form "heterocyclyl";
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW1029, -NW1030W1031, -NO 2 , -OH, -
- W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 are independently selected from the group consisting of: "alkyl, alkyl, cycloalkyl, cycloalkylalkyl (Cg-C 30), heterocyclyl, heterocyclylalkyl,
- W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 20 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- W1 108, W1109, W11 10, W1 11 1, W1 112, W11 13, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121, W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128, W1 129, W1130, W1131, W1 132 are independently selected from the group consisting of: "alkyl, (Cg-)
- W1 170, W1171, W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181, W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 145, W1146 and / or W1 154, W1155 and / or W1 167, W1 168 and / or W1174, W1 175 and / or W1 183, W1184 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHW 1 191, -NW 1192 W 1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1194, -C (O) O-
- W1239, W1240, W1241, W1242 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively W1 197, W1 198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 may together also form "heterocyclyl";
- radicals Z3, Z4 or both radicals Z3, Z4 are independently selected from the group consisting of:
- radicals Z10, Z11 or both radicals Z10, Z1 1 and radicals Z12, Z13 being selected independently of one another from the group consisting of:
- Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 are independently selected are selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q10, Q11 and / or Q23, Q24, and or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (a) and / or the substituent group (i) may in turn be independently substituted with at least one substitu
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ50, -NQ51 Q52, -NO 2 , -OH, -OCF 3 , -
- OSi (Q69) (Q70) (Q71), -OS (O 2) -Q72, -NHC (O) -Q73, - NQ74C (O) -Q75, -NH-C (O) -O-Q76, -N HC (O) -NH-Q77, -NH-C (O) -NQ78Q79, -NQ80-C (O) -O-Q81, -NQ82-C (O) -NH-Q83, -NQ84-C (O ) -NQ85Q86, -NHS (O 2 ) -Q87, -NQ88S (O 2 ) -Q89, -S- Q90, -S (0) -Q91, -S (O 2) -Q92, -S (O 2) NH-Q93, -S (O 2) NQ94Q95, -S (O 2) O-Q96, -P ( O) (OQ97)
- Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or or Q94, Q95 may together also form "heterocyclyl"; in which optional substituents of substituent group (ii) 15 can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q108, Q109 and / or Q117, Q1 18 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 can each also together form" heterocyclyl ";
- Q209, Q210, Q21 1 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q166 , Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 independent are selected from the group consisting of: "alkyl,
- substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1, Q312, Q313, Q314 are Q315 independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q270 , Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 may together also form "heterocyclyl";
- Z10, Z11 or none of Z10, Z11 is independently selected from the group consisting of:
- Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q328, Q329 and / or Q337, Q338 and / or
- Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 independent are selected from the group consisting of: "alkyl,
- substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456o, Q456p may together also form "heterocyclyl";
- Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
- alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3,
- Q506, Q507, Q508 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- Q605, Q606, Q607, Q608, Q609, Q610, Q611 are, Q612 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 may each together also form" heterocyclyl ";
- Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are selected independently from each other consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q619, Q620 and / or Q628, Q629 and / or Q641, Q642 and / or Q648, Q649 and / or Q657, Q658 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ665, -NQ666Q667, -NO 2 , -OH, -OCF 3 ,
- heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
- Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1, Q812 , Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are independently selected from the A group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q775, Q776 and / or Q784, Q785 and / or Q797 , Q798 and / or Q804, Q805 and / or Q813, Q814 together can also form "heterocyclyl
- Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are independently selected from the group consisting of: "alkyl, (Cg -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and
- alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHQ873, -NQ874Q875, -NO 2 , -OH,
- OSi (Q892) (Q893) (Q894), -OS (O 2) -Q895, -NHC (O) -Q896, - NQ897C (O) -Q898, -NH-C (O) -O-Q899, -NH -C (O) -NH-Q900, -NH-C (O) -NQ901 Q902, -NQ903-C (O) -O-Q904, -NQ905-C (O) -NH-Q906, -NQ907-C ( O) -NQ908Q909, -
- Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 are independently selected from the group consisting of: "Alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 may together also form "heterocyclyl";
- substituent group (i) "hydrogen, alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least a substituent, the same or different, selected from the group consisting of:
- C 30 alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- Q1130, Q1131 are, Q1132 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, Cyc loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q1087 , Q1088 and / or Q1096, Q1097 and / or Q1 109, Q1 110 and / or Q1 116, Q1 117 and / or Q1 125, Q1 126 may together also form "heterocyclyl";
- NZ8Z9 wherein Z8, Z9 are independently selected from the group consisting of:
- OSi (QI 158) (Q1 159) (Q1 160), -0S (0 2 ) -Q1 161, -NHC (O) -Q1162, -NQ1 163C (O) -Q1 164, -NH-C (O) - O-Q1 165, -NH-C (O) -NH-Q1166, -NH-C (O) -NQ1 167Q1 168, -NQ1169-C (O) -O-Q1 170, -NQ1171 -C (O) - NH-Q1 172, -NQ1173-C (O) -NQ1174Q1 175, - 10 NHS (0 2) -Q1 176, -NQ1177S (O 2) -Q1178, -S-Q1179, -S (O) -
- (Cg-C 30) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively: 20 Q1186, Q1187, Q1188, Q1189, Q1190 independently selected from the group consisting of Q1145, Q1146 and / or Q1154, Q1155 and / or Q1 167, Q1 168
- Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241, Q1242 are independently selected from the group consisting of: "alkyl, (Cg-C3o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively Q1 197,
- Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 may together also form "heterocyclyl";
- U100, U101, U 102, U103, U104 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl "and alternatively U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89
- U98 may in each case also form "heterocyclyl", where optionally substituted substituents of substituent group (ii) may in turn be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
- alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU105, -NU106U107, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
- U151, -P (O) (OU152) (OU153), -Si (U154) (U155) (U156) ", where U105, U106, U107, U108, U10g, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U12g, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
- heterocyclylalkyl aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U1 11, U1 12 and / or U 120, U 121 and / or U133, U134 and / or U140, U141 and / or U149, U150 also together in each case" heterocyclyl "can form;
- Z23 is independently selected from the group consisting of:
- substitution group (a) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein above substituents of the substitution group (a) may be independently optionally substituted with at least a substituent, the same or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
- (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl alkyl are U206, U207, U208 independently selected from the group consisting of , U 164 and / or U 172,
- U202 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- alkyl (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
- heterocyclylalkyl aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 may together also also form" heterocyclyl " ;
- (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
- NU289U290 -NU291-C (O) -O-U292, -N11293-C (O) -NH- U294, -NU295-C (O) -NU296U297, -NHS (O 2) -U298, - NU299S (O 2 ) -U300, U301 -S, -S (O) -U302, -S (O 2) -U303, -S (O 2) NH-U304, -S (O 2) NU305U306, -S (O 2) O-U307, -
- alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br,
- U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and where
- U397 and / or U403, U404 and / or U412, U413 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with
- At least one substituent identical or different, selected from the group consisting of:
- alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU420, -NU421 U422, -NO 2 ,
- U464, U465 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another
- U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U478, U479 and / or U487, U488 and / or U500,
- Rest Z5 is independently selected from the group consisting of:
- A44, A45, A46, A47, A48, A49, A50, A51, A52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, het eroarylalkyl "and wherein alternatively A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may together also form" heterocyclyl "; wherein optionally substituents of the substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are independently selected from the group consisting of: alkyl "alkyl, (Cg-C 30), cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 in each case together also "heterocyclyl"
- A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl” and wherein alternatively A11 1, A1 12 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 may together also form "heterocyclyl";
- one of the radicals Z1, Z2 or both radicals Z1, Z2 are independently selected from the group consisting of: (a) -NZ24Z25; with the proviso that one of the radicals Z24, Z25 or both radicals Z24, Z25 are selected independently of one another from the group consisting of: (1) ,, - C (O) -C (O) -TI, -S (O 2) -NT2T3 "; wherein T1, T2, T3 are independently selected from the group consisting of:
- T4 T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42,
- T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T10, T1 1 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 also together" terocyclyl "can form; wherein optionally substituted substituents of the substitution group (I) independently of one another can also be further substituted by at least one substituent, identical or different, selected from the group consisting of:
- OSi T75) (T76) (T77), -OS (O 2) -T78, -NHC (O) -T79, -NT80C (O) - T81, -NH-C (O) -O-T82, -N HC (O) -NH-T83, -NH-C (O) -NT84T85, -NT86-C (O) -O-T87, -NT88-C (O) -NH-T89, -NT90-C (O ) -NT91T92, -NHS (O 2 ) -T93, -NT94S (O 2 ) -T95, -S-T96, -
- T56 T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90,
- T103, T104, T105, T106, T107 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T62,
- T101 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another With
- At least one substituent identical or different, selected from the group consisting of:
- alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT108, -NT109T110, -NO 2 , -
- T153 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- NT195T196 -NHS (O 2) -T197, -NT198S (O 2) -T199, -S- T200, -S (O) -T201, -S (O 2) -T202, -S (O 2) NH- T203, - S (O 2) NT204T205, -S (O 2) O-T206, - P (O) (OT207) (OT208), -Si (T209) (T210), (T211) "; wherein T160, T161, T162, T163, T164, T165, T166, T167,
- T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T21 1 are independently selected from the group consisting of: "alkyl , (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl "and wherein alternatively T166, T167 and / or T175, T176 and / or T188, T189, and / or
- T195, T196 and / or T204, T205 may together also form “heterocyclyl”; alternatively, T2, T3 may together also form “heterocyclyl”;
- Z24, Z25 or none of Z24, Z25 is also independently selected from the group consisting of:
- T261, T262, T263 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and alternatively T218, T219 and or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc
- T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 also together in each case also Can form "heterocyclyl";
- substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- T366 Si (T365) (T366) (T367) "; wherein T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334 , T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350,
- T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are independently selected from the group consisting of: "alkyl, (Cg-C3o ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may together also form "heterocyclyl";
- radicals Z26, Z27 or both radicals Z26, Z27 are independently selected from the group consisting of:
- T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are independently selected from the group consisting of:
- alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively T374, T375 and / or T381, T382 and / or T391, T392 and or T398, T399 may together also form "heterocyclyl";
- substituents of the substituent group (i) may in turn be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
- NT437-C (O) -NH-T438, -NT439-C (O) -NT440T441, - NHS (O 2) -T442, -NT443S (O 2) -T444, -S-T445, -S (O) - T446, -S (O 2) -T447, -S (O 2) N H-T448, -S (O 2) NT449T450, - S (O 2) O-T451, -P (O) (OT452) (OT453), - Si (T454) (T455), (T456) "; wherein T405, T406, T407, T408, T409, T410, T411, T412 , T413, T414, T415, T416, T417, T418, T419, T420, T421,
- T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are independently selected from the group consisting of
- T41 1, T412 and / or T420, T421 and or T433, T434 and / or T440, T441 and / or T449, T450 may together also form "heterocyclyl";
- (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
- T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are independently selected from the group con- sisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 may together also form "heterocyclyl";
- Z28, Z29 and at least one of Z30 is Z31 independently selected from the group consisting of: (II) "(Cg-C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C (O) - (C 9 -C 30 ) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, - C (O) -heterocyclyl, -C (O) - heterocyclylalkyl, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) - cycloalkyl, (2 O) -S cycloalkyl,
- substitution group (II) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
- T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 are independently selected from the group consisting of
- T606 may each together also form "heterocyclyl";
- (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
- T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are independently selected from the group con- sisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T619 , T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 may each together also form "heterocyclyl";
- Z28, Z29 or none of Z28, Z29 and Z30, Z31 or none of Z30, Z31 and Z32 is independently selected from the group consisting of: (III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl ", where optionally above substituents of the substituent group (IM) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1, T712, T713, T714, T715, T716 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 may together also also form" heterocyclyl "; optional
- T734 T735, T736, T737, T738, T739, T740, T741, T742,
- T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are independently selected from the group consisting of
- alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively T723, T724 and / or T732, T733 and / or T745, T746 and or T752, T753 and / or T761, T762 may together also form "heterocyclyl";
- (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of: (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHT769, - NT770T771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
- OSi (T788) (T789), (T790), -OS (O 2) -T791, -NHC (O) -T792, -NT793C (O) -T794, -NH-C (O) -O-T795, -NH -C (O) -NH-T796, -NH-C (O) -NT797T798, -NT799-C (O) -O-T800, -NT801 -C (O) -NH-T802, -NT803-C ( O) - NT804T805, -NHS (O 2) -T806, -NT807S (O 2) -T808, -S-S-
- NT836T837 -OP (O) (OT838) (OT839), -OSi (T840) (T814), (T842), -OS (O 2) -T843, -NHC (O) -T844, -NT845C (O) -T846 , -NH-C (O) -O-T847, -NHC (O) -NH-T848, -NH-C (O) -NT849T850, -NT851-C (O) -O-T852, -NT853- C (O) -NH-T854, -NT855- C (O) -NT856T857, -NHS (O 2) -T858, -NT859S (O 2) -T860, -S-S-
- T870, T871, T872 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" and wherein alternatively T827, T828 and / or
- T866 may together also form "heterocyclyl", wherein optionally substituents of the substituent group (i) above may also be further substituted independently of one another
- alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT873, -NT874T875, -NO 2 , -
- OSi T892 (T893), (T894), -OS (O 2) -T895, -NHC (O) -T896 - NT897C (O) -T898, -NH-C (O) -O-T899, -NH -C (O) -NH-T900, -NH-C (O) -NT901T902, -NT903-C (O) -O-T904, - NT905-C (O) -NH-T906, -NT907-C (O ) -NT908T909, -
- T924 T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897 , T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, 5 T908, T909, T910, T911, T912, T913, T914, T915, T916,
- T917, T918, T919, T920, T921, T922, T923, T924 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl
- T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 may together also form "heterocyclyl"; optionally substituents of the substituent group (ii) above may be substituted independently of one another
- NEN having at least one substituent, the same or different, selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT925, -
- T969, T970, T971, T972, T973, T974, T975 are, T976 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 can each also together form" heterocyclyl ";
- radicals Z26, Z27 or none of the radicals Z26, Z27 independently of one another is also selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -
- OSi T996) (T997), (T998), -OS (O 2) -T999, -NHC (O) -TIOOO, - NT1001C (O) -TI002, -NH-C (O) -O-TI003, -NH -C (O) -NH-TI004, -NH-C (O) -NTI005T1006, -NT1007-C (O) -O-TI008, -NT1009-C (O) -NH-TIOIO 1 -NTIOII-C (O ) -NTIO ⁇ TIOIS 1 -NHS (O 2 ) - T 1014, -NT 10 15 S (O 2 ) -T 10 16, -S-T 10 17, -S (O) -TiO 18, -S (O 2 ) -
- T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 are independently selected are selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and alternatively T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 may together also form "heterocyclyl"; in which optional substituents of substituent group (i) may in turn also be further substituted with at least one substituent
- T1056 -NH-C (O) -NTI057T1058, -NT1059-C (O) -O-TI060, -NT1061-C (O) -NH-TI062, -NT1063-C (O) -NTI064T1065, -NHS (O 2) -T1066, -NT1067S (O 2) -T1068, -S-T1069, -S (O) - T1070, -S (O 2) -T1071, -S (O 2) NH-TI072, -S (O 2 ) NTI073T1074, -S (O 2 ) O-TI075, -P (O) (OTI076) (OT1077),
- T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 are independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T 1035, T 1036 and / or T 1044, T 1045 and / or T 1057, T 1058 and or T1064, T1065 and / or T1073, T1074 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of
- alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1081, -NT1082T1083, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 084, -
- T1 126 may together also form "heterocyclyl"; and one of the radicals Z1, Z2 or none of the radicals Z1, Z2 is independently selected from the group consisting of:
- T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181, T1 182, T1 183, T1184 are independently selected from the group consisting of: "alkyl, (Cg -
- T1 139, T1140 and / or T1148, T1 149 and / or T1 161, T1162 and / or T1168, T1 169 and T1177, T1 178 may together also form "heterocyclyl"; optionally optionally substituents of the substituent group (c) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of: "Alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N
- T1234 (T1235) (T1236) "where T1 185, T1186, T1 187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219,
- T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
- T1191, T1 192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above are also independent may be substituted with at least one substituent, identical or different, selected from the group consisting of:
- NT1269-C (O) -NH-T1270, -NT1271-C (O) -NT1272T1273, - NHS (O 2) -T1274, -NT1275S (O 2) -T1276, -S-T1277, -S (O) - T1278, -S (O 2) -T1279, -S (O 2) NH-T1280, -S (O 2) NT1281T1282, - S (O 2) O-TI283, -P (O) (OTI284) (OT1285) , Si (T1286) (T1287) (T1288) "; wherein T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254 , T1255, T1256, T1257, T1258, T1259, T1260, T126
- T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
- T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 may together also form "heterocyclyl";
- OSi (T1308) (T1309) (T1310), - OS (O 2) -T1311, -NHC (O) -T1312, - NT1313C (O) -TI314, -NH-C (O) -O-TI315, -NH -C (O) -NH-T1316, -NH-C (O) -NTI317T1318, -NT1319-C (O) -O-TI320, -NT1321-C (O) -NH-T1322, -NT1323-C (O ) -NTI324T1325, - NHS (O 2 ) -T 1326, -NT 1327S (O 2 ) -T 1328, -S-T 1329, -S (O) -
- T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, are T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and
- alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1341, -NT1342T1343, -NO 2 , -
- alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT1393, -NT1394T1395,
- NT1408T1409 -OP (O) (OTI410) (OTI411), - OSi (T1412) (T1413) (T1414), -OS (O 2) -T1415, -NHC (O) - T1416, -NT1417C (O) -T1418 , -NH-C (O) -O-TI419, -NH-C (O) -NH-TI420, -NH-C (O) -NT1421T1422, -NT1423-
- T1400 T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427,
- T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 can in each case also form" heterocyclyl ";
- T1445, T1446, T1447 are independently selected from the group consisting of: (I)" hydrogen , alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1448 , -NT1449T1450, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , - SO 3 H, -P (O) (OH) 2, -C
- T1497 T1498) (T1499) "; wherein T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466 , T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478,
- T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492 , T1493 together can also form 5 "heterocyclyl"; wherein optionally substituted substituents of the substitution group (I) may be independently further substituted with at least one substituent, same or different, selected from the
- T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 each may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least
- T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alter-
- T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 may together also form "heterocyclyl", wherein optionally substituents of the substituent groups above
- 10 pe (ii) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
- T1630 -NH-C (O) -NH-TI631, -NH-C (O) -NT1632T1633, -NT1634-C (O) -O-TI635, -NT1636-C (O) -NH-TI637, -NT1638 -C (O) -NTI639T1640, - NHS (O 2) -T1641, -NT1642S (O 2) -T1643, -S-T1644, -
- T1604 T1605, T1606, T1607 , T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651,
- T1652, T1653, T1654 is, T1655 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively T1610, T161 1 and / or
- T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 may each also together form "heterocyclyl", alternatively T1446, T1447 may together also form "heterocyclyl";
- (I) is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl, -C (O) alkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) - cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -
- alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
- NHT1670 -O-C (O) -NTI 671 T1672, - OP (O) (OTI 673) (OT1674), -OSi (TI 675) (T1676) (T1677), - OS (O 2 ) -T1678, NHC (O) -TI 679, -NT1680C (O) -TI 681, -NH-C (O) -O-TI 682, -NH-C (O) -NH-TI 683, -NH-C (O) -
- T1703, T1704, T1705, T1706, T1707 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and whereby
- T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 in each case together can also form "heterocyclyl", where optionally substituents of the substituent group (i) optionally substituted further independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
- alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
- T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 are independently selected from the group consisting of: "alkyl, (C 9 - 30) C alkyl,
- substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
- alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1760, -NT1761T1762, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
- OSi (TI779) (T1780) (T1781), -OS (O 2) -T1782, - NHC (O) -TI783, -NT1784C (O) -TI785, -NH-C (O) -O- T1786, -NH -C (O) -NH-TI787, -NH-C (O) -NT1788T1789, -NT1790-C (O) -O-TI791, -NT1792-
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
L'invention concerne de nouveaux dérivés de pyrido[2,3-b]pyrazine de formules générales (I) et (II), leur fabrication et leur utilisation en tant que médicaments, notamment pour le traitement de maladies malignes et autres, provoquées par une prolifération cellulaire pathologique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06819385A EP1957487A1 (fr) | 2005-11-11 | 2006-11-10 | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73569805P | 2005-11-11 | 2005-11-11 | |
EP05024693A EP1785423A1 (fr) | 2005-11-11 | 2005-11-11 | Pyridopyrazines et leur utilisation en tant que modulateurs de kinases |
US84976106P | 2006-10-06 | 2006-10-06 | |
PCT/EP2006/068322 WO2007054556A1 (fr) | 2005-11-11 | 2006-11-10 | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
EP06819385A EP1957487A1 (fr) | 2005-11-11 | 2006-11-10 | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1957487A1 true EP1957487A1 (fr) | 2008-08-20 |
Family
ID=37654792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06819385A Withdrawn EP1957487A1 (fr) | 2005-11-11 | 2006-11-10 | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1957487A1 (fr) |
JP (1) | JP5527972B2 (fr) |
KR (1) | KR101400905B1 (fr) |
AR (1) | AR060010A1 (fr) |
AU (1) | AU2006313701B2 (fr) |
CA (1) | CA2628039A1 (fr) |
HK (1) | HK1126474A1 (fr) |
IL (1) | IL191139A0 (fr) |
NO (1) | NO20082511L (fr) |
WO (1) | WO2007054556A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1790342A1 (fr) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1990342A1 (fr) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Dérivés de pyridopyrazine, processus de fabrication et utilisations correspondantes |
EP2170338A2 (fr) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulation de la régulation d'énergie et de la fonction cérébrale par adn-pkcs |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8846723B2 (en) | 2010-07-29 | 2014-09-30 | Eastman Chemical Company | Esters of O-substituted hydroxy carboxylic acids and preparations thereof |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2508184A1 (fr) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007079999A2 (fr) * | 2005-11-11 | 2007-07-19 | Æterna Zentaris Gmbh | Derives pyridopyrazine et utilisation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3809695A (en) | 1967-04-19 | 1974-05-07 | Degussa | 2,6-dichloro-3-nitro-pyridine |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
CA2172750A1 (fr) | 1995-03-28 | 1996-09-29 | Shinzo Seko | Methode de preparation d'aminonitropyridines |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
WO1999032111A1 (fr) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees |
WO2000035435A1 (fr) | 1998-12-15 | 2000-06-22 | Warner-Lambert Company | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek |
EE200100339A (et) | 1998-12-22 | 2002-10-15 | Warner-Lambert Company | Kombineeritud kemoteraapia |
EP1278748B1 (fr) | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine |
EP1301472B1 (fr) | 2000-07-19 | 2014-03-26 | Warner-Lambert Company LLC | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
BR0212510A (pt) | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
WO2003068223A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Urees aryliques a kinase de raf et activite inhibitrice d'angiogenese |
EP1496981A2 (fr) | 2002-04-08 | 2005-01-19 | Merck & Co., Inc. | Methode de traitement du cancer |
AU2003223467B2 (en) | 2002-04-08 | 2007-10-04 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AU2003230802B2 (en) | 2002-04-08 | 2007-08-09 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AU2003281340B2 (en) | 2002-07-02 | 2009-04-09 | Southern Research Institute | Inhibitors of FtsZ and uses thereof |
AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
EP1636228B1 (fr) * | 2003-05-23 | 2008-10-22 | AEterna Zentaris GmbH | Nouvelles pyridopyrazines et leur utilisation en tant que modulateurs de kinases |
CN1816543B (zh) * | 2003-06-05 | 2011-01-19 | 赞塔里斯有限公司 | 具有细胞凋亡诱导效应的吲哚衍生物 |
WO2005007099A2 (fr) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Inhibiteurs de la pkb utilises comme agents antitumoraux |
CN1902193B (zh) | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
-
2006
- 2006-11-10 WO PCT/EP2006/068322 patent/WO2007054556A1/fr active Application Filing
- 2006-11-10 AU AU2006313701A patent/AU2006313701B2/en not_active Ceased
- 2006-11-10 JP JP2008539443A patent/JP5527972B2/ja not_active Expired - Fee Related
- 2006-11-10 CA CA002628039A patent/CA2628039A1/fr not_active Abandoned
- 2006-11-10 KR KR1020087014068A patent/KR101400905B1/ko not_active IP Right Cessation
- 2006-11-10 EP EP06819385A patent/EP1957487A1/fr not_active Withdrawn
- 2006-11-13 AR ARP060104949A patent/AR060010A1/es unknown
-
2008
- 2008-04-29 IL IL191139A patent/IL191139A0/en unknown
- 2008-06-03 NO NO20082511A patent/NO20082511L/no not_active Application Discontinuation
-
2009
- 2009-05-26 HK HK09104745.1A patent/HK1126474A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007079999A2 (fr) * | 2005-11-11 | 2007-07-19 | Æterna Zentaris Gmbh | Derives pyridopyrazine et utilisation |
Also Published As
Publication number | Publication date |
---|---|
JP2009515853A (ja) | 2009-04-16 |
JP5527972B2 (ja) | 2014-06-25 |
NO20082511L (no) | 2008-06-24 |
KR101400905B1 (ko) | 2014-05-29 |
AU2006313701B2 (en) | 2012-05-31 |
HK1126474A1 (en) | 2009-09-04 |
KR20080068117A (ko) | 2008-07-22 |
CA2628039A1 (fr) | 2007-05-18 |
AU2006313701A1 (en) | 2007-05-18 |
IL191139A0 (en) | 2008-12-29 |
WO2007054556A1 (fr) | 2007-05-18 |
AR060010A1 (es) | 2008-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1957487A1 (fr) | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases | |
US8217042B2 (en) | Pyridopyrazines and their use as modulators of kinases | |
US11655246B2 (en) | Aminothiazole compounds as inhibitors of CTPS1 | |
JP6997766B2 (ja) | 統合的ストレス経路のモジュレーター | |
ES2703723T3 (es) | Métodos para usar inhibidores de MEK | |
JP5805763B2 (ja) | C型肝炎ウイルス阻害剤 | |
EP2504336B1 (fr) | Nouveaux dérivés de naphtyridine et l'utilisation associée en tant qu'inhibiteurs de kinase | |
EP1962854B1 (fr) | Derives de la pyridopyrazine et leur utilisation comme modulateur des voies de transduction de signaux | |
JP6145179B2 (ja) | ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 | |
EP2788000B1 (fr) | Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus | |
JP6585158B2 (ja) | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 | |
WO2007058322A1 (fr) | Composé contenant un groupe basique et son utilisation | |
UA120382C2 (uk) | 1,3-тіазол-2-ілзаміщені бензаміди | |
WO2018052967A1 (fr) | Composés de chromane-8-carboxamide substitués et analogues de ceux-ci, et procédés les utilisant | |
TW200938549A (en) | Compounds | |
KR20190026731A (ko) | 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 | |
EP3492454A1 (fr) | Composés | |
JP2013515733A (ja) | β−トリプターゼインヒビターとしてのインドリル−ピペリジニルベンジルアミン | |
CN101356173B (zh) | 新的吡啶并吡嗪和它们作为激酶调节剂的用途 | |
KR20240038996A (ko) | 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물 | |
JP7295019B2 (ja) | 7-置換1-アリール-ナフチリジン-3-カルボン酸アミドおよびその使用 | |
WO2024026486A2 (fr) | Inhibiteurs de cdk2 et leurs procédés d'utilisation | |
RU2515944C9 (ru) | ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ) | |
TWI392675B (zh) | 新穎之吡啶並吡嗪類及其作為激酶調節劑之用途 | |
MX2008006066A (en) | Novel pyridopyrazines and their use as modulators of kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080506 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20110913 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20150202 |